Literature DB >> 28839958

Esophageal cancer developed in a radiated field: can we reduce the risk of a poor prognosis cancer?

Marina Schena1, Angelo F Battaglia1, Fernando Munoz2.   

Abstract

Entities:  

Year:  2017        PMID： 28839958      PMCID： PMC5542944          DOI： 10.21037/jtd.2017.06.45

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  23 in total

1.  Multiple head and neck tumors: evidence for a common clonal origin.

Authors:  G C Bedi; W H Westra; E Gabrielson; W Koch; D Sidransky
Journal:  Cancer Res       Date:  1996-06-01       Impact factor: 12.701

2.  Risk of treatment-related esophageal cancer among breast cancer survivors.

Authors:  L M Morton; E S Gilbert; P Hall; M Andersson; H Joensuu; L Vaalavirta; G M Dores; M Stovall; E J Holowaty; C F Lynch; R E Curtis; S A Smith; R A Kleinerman; M Kaijser; H H Storm; E Pukkala; R E Weathers; M S Linet; P Rajaraman; J F Fraumeni; L M Brown; F E van Leeuwen; S D Fossa; T B Johannesen; F Langmark; S Lamart; L B Travis; B M P Aleman
Journal:  Ann Oncol       Date:  2012-06-27       Impact factor: 32.976

3.  Radiation therapy for breast cancer and increased risk for esophageal carcinoma.

Authors:  H Ahsan; A I Neugut
Journal:  Ann Intern Med       Date:  1998-01-15       Impact factor: 25.391

4.  Second primary tumors after radiotherapy for malignancies. Treatment-related parameters.

Authors:  Wolfgang Dörr; Thomas Herrmann
Journal:  Strahlenther Onkol       Date:  2002-07       Impact factor: 3.621

Review 5.  Neoadjuvant chemoradiotherapy or chemotherapy? A comprehensive systematic review and meta-analysis of the options for neoadjuvant therapy for treating oesophageal cancer.

Authors:  Han-Yu Deng; Wen-Ping Wang; Yun-Cang Wang; Wei-Peng Hu; Peng-Zhi Ni; Yi-Dan Lin; Long-Qi Chen
Journal:  Eur J Cardiothorac Surg       Date:  2017-03-01       Impact factor: 4.191

Review 6.  Radiation-induced second cancers: the impact of 3D-CRT and IMRT.

Authors:  Eric J Hall; Cheng-Shie Wuu
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-05-01       Impact factor: 7.038

7.  Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.

Authors:  Joel Tepper; Mark J Krasna; Donna Niedzwiecki; Donna Hollis; Carolyn E Reed; Richard Goldberg; Krystyna Kiel; Christopher Willett; David Sugarbaker; Robert Mayer
Journal:  J Clin Oncol       Date:  2008-03-01       Impact factor: 44.544

8.  Effect of Extending the Original Eligibility Criteria for the CROSS Neoadjuvant Chemoradiotherapy on Toxicity and Survival in Esophageal Cancer.

Authors:  E C de Heer; J B Hulshoff; D Klerk; J G M Burgerhof; D J A de Groot; J Th M Plukker; G A P Hospers
Journal:  Ann Surg Oncol       Date:  2017-02-10       Impact factor: 5.344

Review 9.  Concurrent neoadjuvant chemoradiotherapy could improve survival outcomes for patients with esophageal cancer: a meta-analysis based on random clinical trials.

Authors:  Baoxing Liu; Yacong Bo; Kunlun Wang; Yang Liu; Xiance Tang; Yan Zhao; Erjiang Zhao; Ling Yuan
Journal:  Oncotarget       Date:  2017-03-21

Review 10.  Second malignant neoplasms following radiotherapy.

Authors:  Sanath Kumar
Journal:  Int J Environ Res Public Health       Date:  2012-12-18       Impact factor: 3.390
View more
  4 in total

1.  Integrating radiosensitive genes improves prediction of radiosensitivity or radioresistance in patients with oesophageal cancer.

Authors:  Qiuning Zhang; Zhitong Bing; Jinhui Tian; Xiaohu Wang; Ruifeng Liu; Yi Li; Yarong Kong; Yan Yang
Journal:  Oncol Lett       Date:  2019-04-10       Impact factor: 2.967

2.  Fixed-jaw technique to improve IMRT plan quality for the treatment of cervical and upper thoracic esophageal cancer.

Authors:  Wei Song; Hong Lu; Jie Liu; Di Zhao; Jun Ma; Biyun Zhang; Dahai Yu; Xinchen Sun; Jinkai Li
Journal:  J Appl Clin Med Phys       Date:  2019-08-28       Impact factor: 2.102

Review 3.  Radiation-Induced Esophageal Cancer: Investigating the Pathogenesis, Management, and Prognosis.

Authors:  Athanasios Syllaios; Michail Vailas; Maria Tolia; Nikolaos Charalampakis; Konstantinos Vlachos; Emmanouil I Kapetanakis; Periklis I Tomos; Dimitrios Schizas
Journal:  Medicina (Kaunas)       Date:  2022-07-18       Impact factor: 2.948

4.  Selective synergistic anticancer effects of cisplatin and oridonin against human p53-mutant esophageal squamous carcinoma cells.

Authors:  Huiyu Yang; Jie Wang; Suliman Khan; Yuanying Zhang; Kuicheng Zhu; Enhui Zhou; Meiyuan Gong; Bingrong Liu; Quancheng Kan; Qi Zhang
Journal:  Anticancer Drugs       Date:  2022-01-01       Impact factor: 2.248
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.